Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860783 | 0.87 | POLB (0.33) | PTGS1PTGS2MAOAKMT2AKDM1A | |
| SCHEMBL6856188 | 0.79 | GSK3B (0.34) | PTGS1PTGS2KMT2AGAAPOLB | |
| SCHEMBL6863283 | 0.79 | GAA (0.35) | PTGS1PTGS2GAAPOLBRAB9A | |
| SCHEMBL6861913 | 0.78 | GAA (0.34) | KMT2AGAAPOLBRAB9A | |
| SCHEMBL6862891 | 0.78 | CA1 (0.33) | PTGS1PTGS2KMT2AGAAPOLB | |
| SCHEMBL9607650 | 0.76 | HTR2C (0.46) | PTGS1PTGS2MAOAKMT2AKDM1A | |
| SCHEMBL6862954 | 0.76 | PTGS1 (0.41) | PTGS1PTGS2MAOAKMT2AKDM1A | |
| SCHEMBL6864166 | 0.73 | GAA (0.36) | PTGS1PTGS2KMT2AGAAPOLB | |
| SCHEMBL6856418 | 0.73 | GAA (0.38) | PTGS1PTGS2KMT2AGAAPOLB | |
| SCHEMBL6862798 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794471-B2 | OF A HYDROXYHYDROCARBYL- OR MERCAPTOHYDROCARBYL- DITHIOLANE; CURED OPTICAL ARTICLE FORMED BY PHOTOPOLYMERIZING THE ACRYLATE | MITSUI CHEMICALS, INC. (JP) | 2004-09-21 | — | — | US | disclosed |
| EP-1193264-B1 | Acrylic ester compound and usage thereof | MITSUI CHEMICALS INC (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20020061995-A1 | Acrylic ester compound and usage thereof | MITSUI CHEMICALS, INC. (JP) | 2002-05-23 | — | — | US | disclosed |
| EP-1193264-A1 | Acrylic ester compound and usage thereof | Mitsui Chemicals, Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061995-A1 | Acrylic ester compound and usage thereof | ASS1, HAT1, EIF2B1 | PTGS1 303/4885PTGS2 1099/4885MAOA 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.